



FACULTY OF PHARMACY
IN HRADEC KRÁLOVÉ
Charles University

Diploma Thesis

Synthesis of Substituted Arylguanidines as Potential Drugs XI.

Author: Firdaus Shaban Swedi
Supervisor: PharmDr. Karel Palát CSc.

Hradec Kralove, 2015

Declaration

I hereby declare that, this thesis is my own original copyrighted work. All literature and other resources used herein directly or indirectly are properly cited and listed in the References. This thesis was not misused for obtaining the same or different academic degree.

Date: 15th May 2015

Signature:

Acknowledgments

I wish to express my sincere gratitude to the Almighty God for His favours bestowed upon me. I am thankful to my family for their continuous support throughout my study and my supervisor assoc. prof. PharmDr. Palat CSc., for his efforts and support in making this project a success.

Furthermore, i would like to acknowledge assoc. prof. PharmDr. J. Kuneš, CSc. and I. Vencovská for their contributions to the analysis of NMR and IR spectra. Mgr. M. Vejsová, PhD., PharmDr. P. Jílek, CSc., and I. Dufková for their contributions to the evaluation of the biological activity. Lastly, I would like to thank the Faculty of Pharmacy, Charles University for its profound impact on my education.

Abstract

This study focus on synthesis of novel compounds as potential agents for the therapy of mycoses. The following four novel compounds were synthesized:

1-(4-(octylsulfanyl)-3-(trifluormethyl)phenyl)guanidine,

1,1-dimethyl-3-(4-(octylsulfanyl)-3-(trifluormethyl)phenyl)guanidine,

1-(4-(decylsulfanyl)-3-(trifluormethyl)phenyl)guanidine,

3-(4-(decylsulfanyl)-3-(trifluormethyl)phenyl)-1,1-dimethylguanidine.

All intermediary and final crystalline products formed were thoroughly purified and characterized by Thin Layer Chromatography (TLC) and Melting points. Structures were elucidated on the basis of Infrared (IR) and Nuclear Magnetic Resonance (NMR) spectroscopy. 1-(4-(octylsulfanyl)-3-(trifluormethyl)phenyl)guanidine was evaluated for *in vitro* antimicrobial activity on different fungal and bacterial strains.

Abstrakt

Tato studie se zabývá syntézou nových látek s potenciálem k léčbě mykóz, z nichž byly připraveny následující čtyři:

1-(4-(octylsulfanyl)-3-(trifluormethyl)fenyl)guanidin,

1,1-dimethyl-3-(4-(octylsulfanyl)-3-(trifluormethyl)fenyl)guanidin,

1-(4-(decylsulfanyl)-3-(trifluormethyl)fenyl)guanidin,

3-(4-(decylsulfanyl)-3-(trifluormethyl)fenyl)-1,1-dimethylguanidin.

Všechny průběžné a finální krystalické produkty byly důkladně vyčištěny a jejich identita potvrzena tenkovrstvou chromatografií (TLC) a teplotou tání. Struktura produktů byla charakterizována prostřednictvím infračervené (IR) spektroskopie a nukleární magnetické rezonance (NMR). U 1-(4-(octylsulfanyl)-3-(trifluormethyl)fenyl)guanidinu byla vyhodnocena *in vitro* antimikrobiální aktivita na několika mykotických a bakteriálních kmenech

Table of Content

Contents

Declaration.....	i
Acknowledgments.....	ii
Abstract.....	iii
Abstrakt.....	iii
Table of Content.....	iv
1. Introduction	1
2. Theoretical Part.....	2
2.1. Mycosis	2
2.2. Current Trends in mycoses	2
2.3. Current Therapy.....	2
2.4. Future Goal	3
3. Aim of the Project	8
3.1. General Reaction Scheme.....	9
4. Experimental.....	10
4.1. Materials and methods	10
4.2. Methodology.....	10
4.3. Synthesis of a Catalyst.....	11
4.4. Synthesis of octylsulfanyl derivatives	12
Step 1: Synthesis of -4-nitro-1-octylsulfanyl-2-trifluoromethyl benzene.....	12
Step 2: Synthesis of 4-octylsulfanyl-3-trifluoromethylaniline.....	14
Step 3: Synthesis 4-octylsulfanyl-3-trifluoromethylammonium chloride.....	16
Step 4a: Synthesis of 1-(4-octylsulfanyl)-3-(trifluoromethyl)phenylguanidine	18
Step 4b: Synthesis of 1,1-dimethyl-3-(4-(octylsulfanyl)-3-(trifluoromethyl)phenyl)guanidine	22
4.5. Synthesis of decylsulfanyl derivatives.....	26
Step 1: Synthesis of 4-nitro-1-decylsulfanyl-2-trifluoromethyl benzene	26
Step 2: Synthesis of 4-decylsulfanyl-3-trifluoromethylaniline	30
Step 3: Synthesis 4-decylsulfanyl-3-trifluoromethylammonium chloride	31
Step 4a: Synthesis of 1-(4-decylsulfanyl)-3-(trifluoromethyl)phenylguanidine	35
Step 4b: Synthesis of 3-(4-(decylsulfanyl)-3-(trifluoromethyl)phenyl)-1,1-dimethylguanidine.....	39

5. Discussion	43
6. Conclusion	45
7. References	46

1. Introduction

Fungal infection (mycosis) has drawn much attention since the middle of 20th century, with development of new chemotherapeutics¹ and increased use of immunosuppressive drugs, tremendous rise of mycosis was observed.

Mycoses cause a wide range of diseases² ranging from superficial infections which involves the skin to disseminating infections which involves the vital organs like the brain, heart and liver. Though mycoses can be overcome by body's self-defence mechanism together with effective medication, this has not been the case for immunocompromised victims like HIV patients, elderly and premature newborns, unlikewise, it has resulted to severe debilitating condition. Currently, the classical treatments available like amphotericin B, fluconazole, and griseofulvin are more challenged due to increasing resistance of fungal strains especially *Candida* species which plays a big role in the spread of most fungal infections. Today, fluconazole¹ is less effective against mutant *Candida* species, with regards to this, there is an urgent need to develop novel compounds with less susceptibility to induced resistance.

Various studies have been carried out in the search of potential and effective alternatives to fungal treatment. Over the past 4 years, there has been an increased discovery of new lead structures with guanidine core which has had an impact in varied therapeutic³ effects including: chemotherapeutics, anti-diabetic, anti-inflammatory and CNS acting drugs.

Guanidine derivatives being one of the most studied chemical agent in recent discoveries, is the main target of our study. Our literature sources were obtained from Sci-Finder, Elsevier, Google scholar and literature books. Keywords used include: guanidine, phenylguanidine, arylguanidine, guanidine as antifungal. The search was categorized by date i.e. 2012-2015.

2. Theoretical Part

2.1. Mycosis

Mycosis is characterized as a disease caused by fungal strain which invades tissues by means of spores⁴ entering the body through the skin or inhalation. Clinical nomenclature² for mycoses is classified based on site of infection, route of entry and type of virulence exhibited. Approximately 150 out of 100,000 species of fungi⁵ are now recognized to be pathogenic to humans, of these strains the major causative ones in humans are *Candida* and *Aspergillus* species.

2.2. Current Trends in mycoses

The main focus is targeting on the severity of skin and invasive mycoses which contribute immensely to the rise of mycoses worldwide. Superficial mycoses constitutes a prevalence⁶ of 20-25% of all the skin mycoses globally, this clearly indicates a potential problem in the near future. Furthermore, opportunistic mycoses have increased significantly⁷ for the past two decades, posing a huge burden to immunosuppressed victims especially those undergoing organ transplant, HIV patients and those on long term immunosuppressive therapy like corticosteroids.

2.3. Current Therapy


The current approach in treating mycoses is based on the site of infection, mainly categorized as topical or systemic. Amphotericin B remains the gold standard in overcoming invasive and resistant mycoses effectively but it's at highly disadvantage due to its toxic side effects such as nephrotoxicity in prolonged use.

Azole antifungals which include ketoconazole, fluconazole, itraconazole also play a big role in managing both systemic and skin infections, but the treatment is mostly less effective when fungal strains become mutant which finally leads to resistance to treatment.

2.4. Future Goal


In view of the epidemiological studies which indicate emergence of resistance and likeability of decreased response to current treatments, mycoses pose a significant global concern. Contributions towards development of new effective drugs has been the main focus as a result of increased prevalence of mycoses. Guanidines have received much attention due to their free availability^{8,9} in nature as well as vast applications in many fields including: pharmaceuticals, agriculture, and organic chemistry. Furthermore, natural guanidines¹⁰ display potent biological activities due to their unique structure.

Maurizio¹ et al., synthesized novel macrocyclic amidinourea derivatives(I), antimicrobial evaluation exhibited antifungal activity higher or comparable to fluconazole against *Candida* species and potent activity against fluconazole resistant *Candida* strains.




I

Rukhsana⁹ et al., synthesized novel ferrocene-based guanidine derivatives (II). Crystallographic studies of these molecules revealed that existence of strong non-bonding interaction with biological macro-molecules like DNA, inherit good biological activity.




II

According to an article written by Nafees¹¹ et al., tricyclic guanidine analogues of batzelladine K (III) were synthesized, one of the analogues with pentyl and methyl substituents on tricyclic ring exhibited broad spectrum antimicrobial activity. Other analogues exhibited varied antimicrobial spectrum.




(III)

Muhammad¹² et al. synthesized substituted pyridylguanidine derivatives (IV). IR, NMR and XRD studies revealed that synthesized guanidines are stabilized by intramolecular hydrogen bonds. All compounds exhibited excellent inhibition against *Agrobacterium tumefaciens* and aryl substituted pyridylguanidines with substitution at *ortho* and *para* position on the phenyl ring exhibited good to significant antifungal properties against *A. niger* and *F. solani*



IV

A study conducted by Guo Chun¹³ et al. on novel guanidine derivatives(V), exhibited strong killing effect on clinical pathogenic fungi and has potential to overcome defects of strong toxic and side effects as well as drug resistance.



(V)

3. Aim of the Project

This study aims to expound on the search of novel compounds which may be potential candidates in fungal therapy. The focus is on the synthesis of arylguanidines, specifically substituted phenyl guanidines. The following novel compounds will be synthesized in a step by step reaction as shown in the general reaction scheme:


1-(4-(octylsulfanyl)-3-(trifluoromethyl)phenyl)guanidine,

1, 1-dimethyl-3-(4-(octylsulfanyl)-3-(trifluoromethyl) phenyl)guanidine,

1-(4-(decylsulfanyl)-3-(trifluoromethyl)phenyl guanidine,

3-(4-(decylsulfanyl)-3-(trifluoromethyl)phenyl-1,1-dimethylguanidine.

3.1. General Reaction Scheme



4. Experimental


4.1. Materials and methods

All chemicals, solvents and reagents employed in this synthesis were used as obtained from the Aldrich manufacturer without further treatment. Structure identification was confirmed by melting point, Thin Layer Chromatography (TLC), Infrared (IR) and Nuclear Magnetic Resonance (NMR) spectroscopy. Reactions were monitored by TLC using silica-gel plates pre-coated with fluorescent indicator Silufol UV 254(Kavalier) with mobile phase constituting hexane, ethanol and triethylamine in ratio 8:1:0.5. Melting points of the samples were measured with the help of Kofler apparatus and dried over phosphorous pentoxide (P_2O_5) at 61°C and 66 Pa for 24 to 48 hours. IR spectra were measured on Germanium ATR Crystal on Nicolet 6700 FTIR spectrometer and NMR spectra were measured on Varian Mercury-Vx BB 300 Spectrometer in chloroform or DMSO solution.

4.2. Methodology

2-chloro-5-nitrobenzotrifluoride will be employed as the starting chemical compound for the synthesis of all novel compounds. All reaction steps will be carried out under specified conditions. 2-chloro-5-nitrobenzotrifluoride will be made to react with alkylthiols in presence of copper¹⁴ to form alkylsulfanyl derivatives. The resulting products will undergo reduction process¹⁵ to form aniline derivatives. Following reduction, the aniline derivatives will be reacted with dry hydrogen chloride to form ammonium chloride salts. Subsequently, the ammonium chloride salts will be reacted with substituted and unsubstituted cyanamides^{16, 17, 18} to form respective guanidine derivatives.

4.3. Synthesis of a Catalyst



40.00 g (0.16085mol) of copper sulphate pentahydrate was mixed with 140ml of water and the mixture was heated to dissolve. Following dissolution, the solution mixture was left to cool and 12.00g of zinc was then added to the mixture. The reaction was completed in 2 hours confirmed by color change from blue to colorless solution mixture. The mixture was then decanted by hot water and acidified by 5% of hydrochloric acid. Following acidification, the mixture was further decanted by ethanol solution to neutralize the product formed. The product was filtered and the residue was collected and dried in oven.


Result

Mass: 10.00g

Yield: 98%

4.4. Synthesis of octylsulfanyl derivatives

Step 1: Synthesis of -4-nitro-1-octylsulfanyl-2-trifluoromethyl benzene



39.82g (0.2881mol) of potassium carbonate, 120ml of dimethylformamide, 3.05g (0.0480mol) of copper, 20ml (0.1152mol) of octanethiol and 25.00g (0.1108mol) of 2-chloro-5-nitrobenzotrifluoride were mixed together and heated in an oil bath at 150°C. Reaction was completed in 8hrs confirmed by TLC chromatography.


The mixture was filtered, water was added to the filtrate and kept in refrigerator. Crystals formed were purified by recrystallization from ethanol. Final crystals formed were dried and analyzed.

Result


Mass: 12.32g

Yield: 33%

MP: crystals melted below room temperature



Step 2: Synthesis of 4-octylsulfanyl-3-trifluoromethylaniline



10.00g (0.0298mol) of 4-nitro-1-octylsulfanyl-2-trifluoromethylbenzene, 28.25g (0.149mol) of tin (II) chloride and 28ml of ethanol were mixed together and heated under reflux condition with nitrogen gas at 70°C for 8hrs.


The product was left to cool and later alkalized with 50% of sodium hydroxide solution. It was then extracted three times to ethylacetate. The extract was dried by sodium sulfate and distilled off. Residual product was further extracted to hexane and then kept in refrigerator. Crystals formed were purified by recrystallization from ethanol. The final crystals were dried and analyzed.

Result


Mass: 6.00g

Yield: 66%

MP: crystals melted below room temperature



Step 3: Synthesis 4-octylsulfanyl-3-trifluoromethylammonium chloride




5.00g (0.0164mol) of 4-octylsulfanyl-3-trifluoromethylaniline and 100ml of ether were mixed and stirred to dissolve. The solution mixture was then let to cool in an ice bath for 30min. Dry hydrogen chloride was bubbled through the solution mixture. The crystals formed were filtered off, dried and analyzed.

Result


Mass: 2.77g

Yield: 49%

M.pt: 134-138°C



Step 4a: Synthesis of 1-(4-octylsulfanyl)-3-(trifluoromethyl)phenyl)guanidine



0.50g (0.0015mol) of 4-octylsulfanyl-3-trifluoromethylammonium chloride was mixed with 0.10g (0.0023mol) of cyanamide and heated at 120°C . Reaction was completed in 90 minutes confirmed by TLC chromatography.


The product was dissolved in water and acidified with nitric acid. Following acidification, the solution mixture was left to crystallize in refrigerator. Crystals formed were purified by recrystallization from water. Final crystals formed were dried and analyzed

Result

Mass: 0.40g

Yield: 78%


MP: $108-110^\circ\text{C}$



FJ4-1

exp2 CARBON


SAMPLE PRESATURATION
date Apr 17 2013 satmode n
solvent acetone wet n
file exp SPECIAL
ACQUISITION temp not used
sw 18867.9 gain 30
at 0.868 spin 20
mp 32768 hst 0.008
fb 10400 pw90 17.000
bs 4 alfa 10.000
d1 5.000 FLAGS
nt 24000 il n
ct 14276 in n
TRANSMITTER dp y
tn C13 hs mn
sfrq 75.461 PROCESSING
tof 1159.0 lb 0.50
tpwr 50 fn not used
pw 8.500 DISPLAY
DECOUPLER SP 473.4
dn H1 vp 11998.6
dof 0 rfl 4115.8
dm YYY rfp 2995.5
decwave w rp -172.0
dprf 37 lp -396.8
Gmf 8500 FLOT
wc 200
sc 0
vs 840
th nm cdc ph 3




FV4-1

exp1 PROTON

SAMPLE PRESENTATION n
date Apr 17 2013 satmode n
solvent dms0 wet n
file exp SPECIAL
ACQUISITION temp not used
sw 4800.8 gain not used
at 1.706 spin 20
np 16384 hst 0.008
fb 2600 pw90 13.300
bs 32 alfa 10.000
dl 1.000 FLAGS
nt 1 il 1 in n
ct 1 in n
TRANSMITTER dp y
tn H1 hs mn
sfreq 300.071 PROCESSING
tof 340.2 fn not used
tpwr 56 DISPLAY
pw 6.650 sp 48.8
DECOUPLER wp 2998.7
dn C13 rf1 600.0
dof 0 rfp 0
dm nnn fp 147.2
decwave W40_RCN5mm 1p -80.8
dpwr 0 PLOT
dmf 200 wc 200
sc 0
vs 87
th ai cdc ph 7



Step 4b: Synthesis of 1,1-dimethyl-3-(4-(octylsulfanyl)-3-(trifluoromethyl)phenyl)guanidine



0.50g (0.0015mol) of 4-octylsulfanyl-3-trifluoromethylammonium chloride was mixed with 0.16g (0.0023mol) of N, N-dimethylcyanamide and heated at 120°C . Reaction was completed in 90 minutes confirmed by TLC chromatography.


The product was then dissolved in water and alkalized with 5% of sodium hydroxide solution. Following alkalization, the solution mixture was extracted three times in diethyl ether and ethylacetate. The extract was dried by sodium sulfate and distilled off. Residual product was dissolved in water, acidified with nitric acid and kept in refrigerator. Crystals formed were purified by recrystallization from water. Final crystals formed were dried and analyzed.

Result

Mass: 0.38g

Yield: 69%


M.pt: $79.3\text{-}80.1^\circ\text{C}$



FS-4-2

exp707 CARBON


SAMPLE PRESATURATION
date Apr 16 2015 satmode n
solvent cdcl3 wet n
file exp SPECIAL
ACQUISITION temp 25.0
sw 31250.0 gain 30
at 1.049 spin not used
np 65536 hst 0.008
fb 17000 pw90 11.300
bs 1 alfa 10.000
d1 3.000 FLAGS
nt 1000 i1 n
ct 427 in n
tn c13 hs nn
TRANSMITTER dp y
sfreq 125.705 PROCESSING
tof 1913.9 lb 1.00
tpwr 55 fn not used
pw 5.650 DISPLAY
DECOUPLER sp 1231.5
dn H1 wp 18825.5
dcf 0 rfl 11480.3
dm YYY rfp 9678.2
decwave w rp -84.5
dpwr 41 lp
dmf 12346 PLOT
wc 200
sc 0
vs 106
th nm
cdc ph 1



FS-4-2


exp707 PROTON

SAMPLE PRESATURATION
date Apr 16 2015 satmode n
solvent cdcl3 wet n
file exp SPECIAL
ACQUISITION temp 25.0
sw 8012.8 gain 30
at 2.045 spin not used
np 32768 hst 0.008
fb 4000 pw90 9.100
bs 32 alfa 10.000
dl 1.000 FLAGS
nt 8 il n
ct 8 in n
TRANSMITTER H1 hs
dp Y
tn hs
sfrq 499.866 PROCESSING
tof 499.9 fn not used
tpwr 60 DISPLAY
pw 4.550 SP 30.1
DECOUPLER wp 5160.6
dn C13 rfl 1007.2
dof 0 rfp 0
dm nnn rp 161.7
decwave W40_OneNMR-1p 0
PLOT
dpwr 37 WC 200
dmf 32258 SC 0
vs 111
th
ai cdc ph 7



4.5. Synthesis of decylsulfanyl derivatives

Step 1: Synthesis of 4-nitro-1-decylsulfanyl-2-trifluoromethyl benzene



39.82g (0.2881mol) of potassium carbonate, 120ml of dimethylformamide, 3.05g (0.0480mol) of copper, 24ml (0.1152mol) of decanethiol and 25g (0.1108mol) of 2-chloro-5-nitrobenzotrifluoride were mixed together and heated in an oil bath at 150°C. Reaction was completed in 8hrs confirmed by TLC chromatography.


The mixture was filtered, water was added to the filtrate and kept in refrigerator. Crystals formed were purified by recrystallization from ethanol. Final crystals formed were dried and analyzed.

Result

Mass: 27.07g

Yield: 67%


MP: crystals melted below room temp



FS-2-1

exp2 CARBON


SAMPLE PRESATURATION
 date May 14 2015 satmode n
 solvent dmsc wet n
 file exp SPECIAL
 ACQUISITION temp not used
 sw 18867.9 gain 30
 at 0.868 spin 20
 np 32768 hst 0.008
 fb 10400 pw90 19.000
 bs 1 alfa 10.000
 dl 5.000 FLAGS
 nt 24000 il n
 ct 3284 in n
 TRANSMITTER dp y
 tn C13 hs nn
 sfrq 75.461 PROCESSING
 tof 1159.0 lb 1.00
 tpwr 50 fn not used
 PW 9.500 DISPLAY
 DECOUPLER SP 543.7
 dn H1 wd 11004.8
 dof 0 rfl 1134.2
 dm XY rfd 0
 decwave w rp -170.7
 dpwr 37 lp -345.2
 dmf 8500 PLOT
 wc 200
 sc 0
 vs 101
 th 1
 nm cdc ph




FS-2-1

exp2 PROTON

SAMPLE PRESATURATION n
date May 14 2015 satmode n
solvent dmsc wet n
file exp SPECIAL
ACQUISITION temp not used
sw 4800.8 gain not used
at 1.706 spin 20
np 16384 hst 0.008
fb 2600 pw90 13.500
bs 32 alfa 10.000
dl 2.000 FLAGS
nt 16 il n
ct 16 in n
TRANSMITTER dp y
tn H1 hs mn
sfrq 300.071 PROCESSING
tof 340.2 fn not used
tpwr 56 DISPLAY
pw 6.750 sp 75.7
DECOUPLER wp 2568.6
dn C13 rfl 600.0
dof 0 rfp 0
dm nmn rp 154.4
decwave W40_HCN5mm lp -89.2
dprz 0 PLOT
dmf 200 wc 200
sc 0
vs 94
th 7
ai cdc ph



Step 2: Synthesis of 4-decylsulfanyl-3-trifluoromethylaniline



10.00g (0.0275mol) of 4-nitro-1-decylsulfanyl-2-trifluoromethylbenzene, 26.07g (0.1395mol) of tin (II) chloride and 28ml of ethanol were mixed together and heated under reflux condition with nitrogen gas at 70°C for 8hrs.

The product was left to cool and later alkalized with 50% of sodium hydroxide solution. It was then extracted three times in ethylacetate. The extract was dried by sodium sulfate and distilled off. Residual product was further extracted in hexane and then kept in refrigerator. Crystals formed were purified by recrystallization from ethanol. The final crystals were dried and analyzed.


Result

Mass: 8.66g

Yield: 94%

MP: 30.3-30.5°C

Step 3: Synthesis 4-decylsulfanyl-3-trifluoromethylammonium chloride




8.00g (0.0239mol) of 4-decylsulfanyl-3-trifluoromethylaniline and 100ml of ether were mixed and stirred to dissolve. The solution mixture was then let to cool in an ice bath for 30min. Dry hydrogen chloride was bubbled through the solution mixture. The crystals formed were filtered off, dried and analyzed.

Result

Mass: 5.82g

Yield: 66 %


M.pt: 130-133°C



FS-2-3

exp2 CARBON


SAMPLE PRESATURATION
date May 14 2015 satmode n
solvent dmsc wet n
file exp SPECIAL
ACQUISITION temp not used
sw 18867.9 gain 30
at 0.868 spin 20
np 32768 hst 0.008
fb 10400 pw90 19.000
bs 1 alfa 10.000
d1 5.000 FLAGS
nt 24000 il n
ct 12670 in n
TRANSMITTER cp y n
tn C13 hs nn
sfrc 75.461 PROCESSING
tof 1159.0 lb 0.50
tpwr 50 fn not used
pw 9.500 DISPLAY
DECOUPLER sp 597.8
dn HI wp 9817.4
dof 0 rfl 4144.6
dm YFF rfp 2995.5
decwave w rp -174.3
dppwr 37 lp -324.1
dmf 8500 PLOT
wc 200
sc 0
vs 87
th 0
mm cdc ph




FS-2-3

exp2 PROTON

SAMPLE PRESATURATION n
date May 14 2015 satmode n
solvent dms0 wet n
file SPECIAL
ACQUISITION temp not used
sw 4800.8 gain not used
at 1.706 spin 20
np 16384 hst 0.008
fb 2600 pw90 13.500
bs 32 alfa 10.000
dl 2.000 FLAGS
nt 16 il n
ct 16 in n
TRANSMITTER dp y
tn H1 hs mn
sfrq 300.071 PROCESSING
tof 340.2 fn not used
tpwr 56 DISPLAY
pw 6.750 SP 75.7
DECOUPLER wp 2551.0
dn C13 xfl 600.0
dof 0 xfp 0
dm nnn xp 153.9
decwave W40_HCN5mm 1p -82.3
dppwr 0 PLOT
dmf 200 wc 200
sc 0
vs 245
th 7
ai cdc ph



Step 4a: Synthesis of 1-(4-decylsulfanyl)-3-(trifluoromethyl)phenylguanidine



0.50g (0.0014mol) of 4-octylsulfanyl-3-trifluoromethylammonium chloride was mixed with 0.09g (0.0027mol) of cyanamide and heated at 120°C . Reaction was completed in 90 minutes confirmed by TLC chromatography.


The product was dissolved in water and acidified with nitric acid. Following acidification, the solution mixture was left to crystallize in refrigerator. Crystals formed were purified by recrystallization from water. Final crystals formed were dried and analyzed.

Result

Mass: 0.45g

Yield: 90 %


MP: $96.3\text{--}96.8^\circ\text{C}$



FS-1

exp707 CARBON


```
SAMPLE PRESATURATION
date May 13 2015 satmode n
solvent dmsc wet n
file exp SPECIAL
ACQUISITION temp 25.0
sw 31250.0 gain 30
at 1.049 spin not used
np 65536 hst 0.008
fb 17000 pw90 11.300
bs 1 alfa 10.000
d1 3.000 FLAGS
nt 1000 il n
ct 1000 in n
TRANSMITTER dp Y
tn C13 hs nn
sfreq 125.705 PROCESSING
tof 1913.9 lb 2.00
tpwr 55 fn not used
pw 5.650 DISPLAY
DECOUPLER sp 1040.1
dn H1 wp 19600.9
dof 0 rfl 1799.0
dm yyy rfp 0
decwave w xp 43.2
dpwr 41 lp 0
dme 12346 PLOT
wc 200
sc 0
vs 244
th 1
nm cdc ph
```




FS-1

exp707 PROTON

```
SAMPLE PRESATURATION
date May 13 2015 satmode n
solvent dms0 wet n
file exp SPECIAL
ACQUISITION temp 25.0
sw 8012.8 gain 44
at 2.045 spin not used
np 32768 hst 0.008
fb 4000 pw90 9.100
bs 32 alfa 10.000
dl 1.000 FLAGS
nt 8 il n
ct 8 in n
TRANSMITTER dp Y
tn H1 hs mn
sfrq 499.869 PROCESSING
tof 499.8 fn not used
tpwr 60 DISPLAY
pw 4.550 sp 79.0
DECOUPLER wd 4956.2
dn C13 rfl 1007.2
dof 0 rfp 0
dm nnn rp 38.1
decwave W40 OneMR-1p 0
PLOT
dpwr _W018 37 wc 200
dmf 32258 sc 0
vs 78
th ai cdc ph 7
```



Step 4b: Synthesis of 3-(4-(decylsulfanyl)-3-(trifluoromethyl)phenyl)-1,1-dimethylguanidine



0.5g (0.0014mol) of 4-octylsulfanyl-3-trifluoromethylammonium chloride was mixed with 0.15g (0.0027mol) of N, N-dimethylcyanamide and heated at 120°C . Reaction was completed in 90 minutes confirmed by TLC chromatogram.


The product was then dissolved in water and alkalinized with 5% of sodium hydroxide solution. Following alkalization, the solution mixture was extracted three times in diethyl ether and ethylacetate. The extract was dried by sodium sulfate and distilled off. Residual product was dissolved in water, acidified with nitric acid and kept in refrigerator. Crystals formed were purified by recrystallization from water. Final crystals formed were dried and analyzed.

Result

Mass: 0.40g

Yield: 80%


MP: $91.9\text{-}92.0^\circ\text{C}$



FS-2

exp2 CARBON


SAMPLE PREPARATION
date May 13 2015 satmode n
solvent cdcl3 wet n
file exp SPECIAL
ACQUISITION temp not used
sw 18867.9 gain 30
at 0.868 spin 20
np 32768 hst 0.008
fb 10400 pw90 19.000
bs 1 alfa 10.000
dl 5.000 FLAGS
nt 24000 il n
ct 11672 in n
TRANSMITTER dp y
tn C13 hs nn
sfreq 75.460 PROCESSING
tof 1159.0 lb 0.50
tpwr 50 fn not used
pw 9.500 DISPLAY
DECOUPLER sp 681.7
dn H1 wd 11494.2
dof 0 rfl 6945.3
dm YYY rfp 5809.8
decwave w xp 114.1
dprw 37 lp -266.6
dmf 8500 PLOT
wc 200
sc 0
vs 200
th 1
nm cdc ph



FS-2

exp2 PROTON

```
SAMPLE      PRESATURATION
date  May 13 2015  satmode  n
solvent  cdcl3  wet      n
file     exp    SPECIAL  n
ACQUISITION  temp  not used
sw  4800.8  gain  not used
at  1.706  spin  20
np  16384  hst   0.008
fb  2600  pw90  13.500
bs  32    alfa  10.000
dl  2.000  FLAGS
nt  16    il   n
ct  16    in   n
TRANSMITTER  dt  y
tn  H1    hs   nn
sfrq  300.070  PROCESSING
tof  340.2  fn   not used
tpwr  56    DISPLAY
pw  6.750  sp   -66.1
DECOUPLER   wp  3195.6
dn  C13  rfl  600.0
dof  0    rfp  0
dm  nn  xp  144.2
decwave W40_HCN5mm  lp  -86.6
dpxr  0    PLOT
dmf  200  wc  200
      sc  0
      vs  110
      th  7
      ai  cdc  ph
```



5. Discussion

In this project, novel compounds were synthesized according to the lab protocols employed in the synthesis of guanidine derivatives.

In the first step on the synthesis of alkylsulfanyl derivatives i.e. 4-nitro-1-octylsulfanyl-2-trifluoromethylbenzene and 4-nitro-1-decylsulfanyl-2-trifluoromethylbenzene and in the second step on the synthesis of aniline derivatives i.e. 4-octylsulfanyl-3-trifluoromethylaniline, was quite challenging in that, crystals formed melted at room temperature and therefore making it difficult to measure the melting points of these intermediary products.

In the third step on the synthesis of ammonium chloride salts i.e. 4-octylsulfanyl-3-trifluoromethylammonium chloride and 4-decylsulfanyl-3-trifluoromethylammonium chloride, was interesting in that, coloured crystals were formed easily and therefore it was easier to work with the crystals.

In the final step, the synthesis of guanidine derivatives was faced with some trials especially in the synthesis of dimethylguanidine derivatives i.e. 1,1-dimethyl-3-(4-(octylsulfanyl)-3-(trifluoromethyl)phenyl)guanidine and 3-(4-(decylsulfanyl)-3-(trifluoromethyl)phenyl)-1,1-dimethyl guanidine. Typical synthesis of dimethylguanidine according to the protocol, the solution mixture after heating reaction is alkalized to form crystals, unfortunately formation of crystals were unsuccessful and therefore guanidine nitrate derivatives were synthesized by acidifying the water solution of the dimethylguanidine derivatives.

Purification of products was achieved by dissolution of products in hot water or hot ethanol with small amount of charcoal in relation to their solubility in respective solvents. In the case of purification of guanidine derivatives, products were dissolved in hot water while in the case of alkylsulfanyl and aniline derivatives, products were dissolved in hot ethanol. Purity and structure identification of all the compounds were

analyzed and confirmed by TLC, melting points, infrared and NMR spectroscopy.

1-(4-octylsulfanyl)-3-(trifluoromethyl)phenylguanidine was evaluated for antimicrobial activity on fungal and bacterial strains in the department of microbiology and medical biology, Faculty of Pharmacy. The results obtained portrayed varying MIC in $\mu\text{mol/L}$ for different strains.

Fungal strains with respective MIC included: *Candida albicans* (15.62), *Candida tropicalis* (7.81), *Candida krusei* (7.81), *Candida glabrata* (7.81), *Trichosporon asahii* (15.62), *Aspergillus fumigates* (15.60), *Absidia corymbifera* (31.25), *Trichophyton mentagrophytes* (7.81)

Bacterial strains with respective MIC included: *Staphylococcus aureus* (3.9), *Staphylococcus aureus* –MRSA (3.9), *Staphylococcus epidermidis* (3.9), *Enterococcus sp.* (7.81), *Escherichia coli* (15.62), *Klebsiella pneumonia* (15.62), *Klebsiella pneumonia*-ESBL (15.62), *Pseudomonas aeruginosa* (15.62)

6. Conclusion

The following novel compounds were successfully synthesized according to the given protocols:

- 1-(4-(octylsulfanyl)-3-(trifluoromethyl) phenyl)guanidine,
- 1, 1-dimethyl-3-(octylsulfanyl)-3-(trifluoromethyl phenyl)guanidine,
- 1-(4-(decylsulfanyl)-3-(trifluoromethyl)phenyl)guanidine,
- 3-(4-(decylsulfanyl)-3-(trifluoromethyl) phenyl)-1,1-dimethylguanidine.

The compound structures were confirmed by IR, NMR spectroscopy, melting points and TLC. 1-(4-octylsulfanyl)-3-(trifluoromethyl)phenyl) guanidine was proved to exhibit antimicrobial activity in fungal strains including: *C.albicans*, *C.glabrata*, and *A.fumigatus* and bacterial strains including: *Escherichia coli*, *Staphylococcus aureus* and *Klebsiella pneumonia*.

According to this study, arylguanidines may be promising agents in the therapy of mycoses and other therapies as well, further research is yet to be investigated to conclude this.

7. References

1. Sanguinetti Maurizio; Sanfilippo Stefania; Castagnolo Daniele; Sanglard Dominique; Posteraro Brunella; Donzellini Giovanni; Botta Maurizio; ACS Med. Chem. Lett. (2013),4,852-857.
2. Thomas J. Walsh; Dennis M.; Dixon, Medical Microbiology. 4th ed. (1996), chapter 75
3. Saczewski Franciszek; Balewski Lukasz ; *Expert Opin. on Ther. Pat.*(2013),23 (8),965-995
4. Mycosis – in Wikipedia:
<http://en.wikipedia.org/w/index.php?title=Mycosis&oldid=659335199>
5. R. Thiel; Townsend Lett. (2013), 365: 95-101
6. Havlickova B; Czaika VA; Friedrich M.; PubMed (2008), 51, Suppl 4:2-15
7. Michael A. Pfaller; Peter G. Pappas; John R. Wingard; DOI:10.1086/504490 (2006),43, suppl 1
8. Zhang Wen-Xiong; Xu Ling; Xi, Zhenfeng; Chem Commun. (2014), DOI: 10.1039/c4cc05291a
9. Gul Rukhsana; Rauf Muhammad Khawar; Badshah Amin; Azam Syed Sikander; Tahir Muhammad Nawaz; Khan Azim; Eur. J. Med. Chem.(2014),85,438-449
10. Roberto G. S. Berlinck; Amaro E. Trindade-Silva; Mario F. C. Santos; Nat. Prod. Rep.(2012),29,1382
11. . Ahmed Nafees; Brahmhatt Keyur G.; Khan Shabana I.; Jacob Melissa; Tekwani Babu L.; Sabde Sudeep; Mitra Debashis; Singh Inder P.; Khan Ikhlas A.; Bhutani Kamlesh K.; Chem. Biol. Drug Des. (2013),81,491-498
12. Said Muhammad; Badshah Amin; Shah Naseer Ali; Khan Hizbullah; Murtaza Ghulam; Vabre Boris; Zargarian Davit; Khan Muhammad Rashid; Molecules (2014),18,10378-10396
13. Guo Chun; Su Xin et al.; CN 20131637576 (2013); In:
<http://www.google.com/patents/CN103739589A?cl=en>
14. M. Rajšner; J. Metyšová; Svátek E.; F. Mikšík; M. Protiva; Collect. Czech. Chem. Commun. (1975), 40, 719
15. F. D. Belamy; K. Ou; Tetrahedron Lett. (1984), 25, 839
16. F. Arndt; B. Rosenau; Ber. Dtsch. Chem. (1917), Ges. 50, 1248
17. F. Arndt; Ber. Dtsch. Chem. Ges. (1913), 46, 3522
18. J. Miller.; J. Chem. Soc. (1949), 2722.